

The supply of plasma-derived medicinal products in the future of Europe

Second edition

CENTRO
NAZIONALE
SANGUE

 PLASMA
ITALIA
italiaplasma.it

with the patronage of



Ministero della Salute

23-24
April 2024
Rome, Italy

An overview of the Japanese blood Services and events affecting the supply of PDMPs in Japan

Ta-Ke Iijima
Manager

International Section
Corporate Strategy Department
Corporate Strategy Division
Japan Blood Products Organization

C.O.I. Disclosure

I have no conflict of interest to disclose.




Today's Topics

- ◆ JB introduction
- ◆ How the donated blood reaches the patients
- ◆ Recent events affecting the supply of PDMPs in Japan
 - ✓ A case of GMP deviation
 - ✓ IVIG shortage due to rapid increase in demand for IVIG
- ◆ Summary



About Japan Blood Products Organization (JB)



**Established in 2012
as a general incorporated association**

About Japan Blood Products Organization (JB)



**Japan Blood Products
Organization**

Philosophy

Bridging Good Faith and Healthcare

Through blood products derived from voluntary non-remunerated blood donations, we contribute to people's health with the highest sense of ethics and responsibility.


Number of staff	approx. 1,200
Sales	€ 223 MM
Net Profit (FY2022)	€ 17 MM ※:€1=JPY160



Organization Locations



Head Office
(15th MSB Tamachi N , Tokyo)



★ Sale Branch Offices



Chitose Plant (Hokkaido)



Central Laboratory (Hyogo)




Kyoto Plant (Kyoto)



Plasma volume allocated for fractionation from JRCS per each company in Japan (FY2023※)

※ scheduled



JB will secure **about more than half** of the total volume of Japanese plasma for fractionation from JRCS



Our Products

< Plasma-derived Medicinal Products (PDMPs) >

- Immune Globulin
- Hyperimmune Globulin (Anti-D, Anti-HBs, Anti-Tatanus)
- Albumin
- Factor VIII
- Antithrombin
- Fibrinogen
- Haptoglobin etc.

Products list of JB



Contracted from Kyowa Kirin for selling these products by JB

(Recombinant Antithrombin)

Contracted from KMB for selling some products by JB



Fibrin glue

ALB, FVIII+vWF, FIX, FX+FVIIa




For a stable supply of PDMPs in Japan: Blood Act

- **Infected with HIV or HCV by unheated blood products**
 - ✓ Patients infected with HIV or HCV through unheated blood products sue the Japanese government and pharmaceutical companies.
 - ✓ The government and the drug companies have fully admitted liability and settled.
- **Blood Act (Act on Securing a Stable Supply of Safe Blood Products)**
 - ✓ With the aim of improving the safety of blood products and ensuring a stable supply, etc., the Basic Philosophy has been established as a guideline for the operation of the blood business.
 - ✓ The principle of domestic self-sufficiency* of blood products from voluntary non-remunerated blood donations and the assurance of a stable supply are stipulated in the philosophy.
 - *Domestic self-sufficiency: This means that blood products used in Japan are, in principle, manufactured from non-remunerated blood donated voluntarily in Japan.
- **Based on the Blood Act, JB operates its business based on the basic principle of Bridging Good Faith and Healthcare (contributing to healthcare in Japan by supplying PDMPs from blood donations made with good faith).**



For a stable supply of PDMPs in Japan



Ensuring transparency in the blood services

Blood division of the Pharmaceutical Affairs and Food Sanitation Council (Advisory body to MHLW Minister)

- To study and deliberate on necessary matters concerning the supply, safety and promotion of the proper use of blood products.
- Ministerial consultations and responses to them
 - ✓ Development and modification of basic policies, blood donation promotion plans and supply and demand plans.
 - ✓ Approval of blood donation acceptance plans.
 - ✓ Licensing and closure of blood collection services.
- Hearing of reports to the Minister.
 - ✓ Status of implementation of supply and demand plans
 - ✓ Periodic reporting of infectious diseases

Blood division meeting steering committee

- Meets quarterly to review and evaluate the following issues and report to the Blood division meeting as necessary.
 - ✓ Periodic reporting of infectious diseases, status of blood services operations, etc.
 - ✓ Status of deliberations by the Investigating Committee
- Held flexibly in emergency situations. Promptly shares and evaluates information on safety, etc., and provides opinions on necessary measures, etc.

Safety technique
investigating
committee

Proper use
investigating
committee

Blood donation
promotion investigating
committee

Recent events affecting the supply of PDMPs in Japan

GMP deviation case by Kaketsuken

- ◆ Manufactured in a manner different from the approved documentation.
- ◆ False record that the products were manufactured in the correct manner.

110 days business suspension order

Products exempted from business suspension for medical reasons (to ensure stable supply) : IVIG, Coagulant factor products.

Other Fractionators


Emergency shipments and unscheduled production increases to contribute to a stable supply.

Entire pharmaceutical industry

- ✓ Inspections of drug manufacturing plants by PMDA without prior notice.
- ✓ PMDA instructs to check discrepancies between drug approval documents and actual manufacturing conditions.


KAKETSUKEN ⇒ Acquired by Meiji Seika Pharma and changed its name to KM Biologics.

A case of supply shortage of IVIG




JB 10% IVIG, Venoglobulin IH[®] (10%VG)

- ✓ IVIG with the most indications in Japan
 - ✓ Liquid 10% formulation
 - ✓ Compared to 5% formulation
 - Half the amount of liquid to be administered
 - Shorter administration time
- ⇒ Easier outpatient management of SID/PID and also of maintenance therapy autoimmune diseases, including CIDP.




Expansion of Indications for Venoglobulin IH®



IVIG & SCIG Launched in Japan

Company	JB		TAKEDA		KMB	CSL Behring	
Product	Venoglobulin IH	Polyglobin N	Glovenin-I	Gammagard	Venilon-I	Privigen	Hizentra
Formulation	5/10% IVIG	5/10% IVIG	5% IVIG	5% IVIG	5% IVIG	10% IVIG	20% SCIG
Type	Liquid	Liquid	Lyophilized	Lyophilized	Lyophilized	Liquid	Liquid
Indications							
PID / SID	✓	✓	✓	✓	✓	✓	✓
IgG2 Deficiency	✓		✓				
Severe Infection	✓	✓	✓	✓	✓		
ITP	✓	✓	✓		✓		
KD	✓	✓	✓		✓		
PM / DM	✓		✓				
CIDP (acute)	✓		✓		✓	✓	
CIDP (Maintenance)	✓		✓			✓	✓
MG	✓		✓				
Pemphigus	✓		✓				
Bullous pemphigoid	✓		✓				
GBS	✓		✓		✓		
Desensitization	✓						
SJS/TEN			✓				
EGPA-ind.neuropathy.					✓		
Optic Neuritis (acute)					✓		

What happened after 10% Venoglobulin(10%VG) was launched



JB could not catch up the demand as the integration process of 2 fractionation facilities was about to begin.

- Some medical institutions have difficulty obtaining IVIG.
- Other companies also limited their supply.



MHLW's measures to improve this situation

- ◆ Requested CSL to increase imports of their IG products
 - ✓ Self-sufficiency << Stable supply.
 - ✓ CSL is the only foreign company holding approval of IVIG in Japan.
- ◆ The 'Approach to permit the addition of indications approved for other companies' IVIGs to one's own IVIG, based on a comparative evaluation of the quality' was made known to the public in June 2023.
 - ✓ This concept is based on a report from public welfare labor scientific research.
 - ✓ Discussions on necessity of clinical trial are still underway due to the following reasons:(1) Unprecedented cases, (2) Unclear applicable conditions



Summary

- ✓ Japan has a Blood Law that aims to protect blood donors, improve the safety of blood products, and ensure a stable supply of these products.
 - The Japanese blood services and PDMPs business operates under this law.
- ✓ JB, as a Japanese plasma fractionator, continues to supply safe and reliable PDMPs for Japanese patients in cooperation with the authorities and JRCS.
- ✓ JB continues to respond to consultations from Southeast Asian countries.



Thank you

